Context Therapeutics (CNTX) Institutional Ownership $2.60 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.64 +0.04 (+1.54%) As of 05/22/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)15TotalInstitutional Inflows(last 12 months)$22.74MNumber ofInstitutional Sellers(last 12 months)7TotalInstitutional Outflows(last 12 months)$14.72M Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Context Therapeutics Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2026 Bank of America Corp DE114,888$301K0.0%+12,213.8%0.125% 5/15/2026 Octagon Capital Advisors LP5,250,000$13.76M1.5%N/A5.714% 5/15/2026 OMERS ADMINISTRATION Corp80,600$211K0.0%N/A0.088% 5/14/2026 Renaissance Technologies LLC182,999$479K0.0%-64.0%0.199% 5/5/2026 Sanctuary Advisors LLC19,316$51K0.0%N/A0.021% 2/23/2026 Virtu Financial LLC28,921$43K0.0%N/A0.031% 2/18/2026 XTX Topco Ltd101,605$149K0.0%+858.8%0.111% 2/18/2026 Quadrature Capital Ltd46,220$68K0.0%N/A0.050% 2/18/2026 Millennium Management LLC2,601,216$3.82M0.0%N/A2.831% 2/17/2026 MPM Bioimpact LLC10,679,391$15.70M1.8%-27.4%11.623% Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/16/2026 Avidity Partners Management LP5,504,855$8.09M2.3%-38.7%5.991% 2/13/2026 Nantahala Capital Management LLC37,837$56K0.0%-97.7%0.041% 2/13/2026 Marshall Wace LLP2,593,198$3.81M0.0%+7,153.7%2.822% 2/13/2026 State Street Corp165,607$243K0.0%+8.5%0.180% 2/12/2026 Renaissance Technologies LLC508,329$747K0.0%+58.8%0.553% 2/9/2026 Blue Owl Capital Holdings LP7,432,906$10.93M0.8%+0.3%8.090% 11/17/2025 Qube Research & Technologies Ltd82,111$80K0.0%-23.1%0.089% 11/17/2025 Nantahala Capital Management LLC1,661,950$1.61M0.1%-14.1%1.809% 11/17/2025 Citadel Advisors LLC103,363$100K0.0%N/A0.112% 11/7/2025Vanguard Group Inc.3,495,031$3.39M0.0%+4.0%3.896% 10/23/2025 Clear Harbor Asset Management LLC92,804$90K0.0%+60.5%0.103% 8/14/2025 Qube Research & Technologies Ltd106,779$70K0.0%-38.7%0.119% 8/13/2025 Affinity Asset Advisors LLC518,025$339K0.0%-21.6%0.578% 8/13/2025 Walleye Capital LLC132,786$87K0.0%-21.4%0.148% 5/16/2025Ally Bridge Group NY LLC1,157,448$708K0.6%-26.6%1.290% 5/15/2025Landscape Capital Management L.L.C.41,216$25K0.0%-54.2%0.046% 5/14/2025Affinity Asset Advisors LLC660,589$404K0.0%-34.9%0.736% 2/17/2025Velan Capital Investment Management LP90,000$94K0.1%-93.0%0.120% 2/17/2025Shay Capital LLC50,000$52K0.0%N/A0.067% 2/17/2025MPM Bioimpact LLC14,705,882$15.44M2.2%N/A19.608% 2/17/2025Millennium Management LLC178,718$188K0.0%+24.2%0.238% 2/17/2025Citadel Advisors LLC29,900$31K0.0%N/A0.040% 2/17/2025Allostery Investments LP950,166$998K1.0%N/A1.267% 2/17/2025Ally Bridge Group NY LLC1,576,762$1.66M1.4%-10.3%2.102% 2/14/2025Jane Street Group LLC27,395$29K0.0%N/A0.037% 2/14/2025Northern Trust Corp113,565$119K0.0%-34.2%0.151% 2/14/2025Blue Owl Capital Holdings LP6,357,928$6.68M1.6%+17.5%8.477% 2/13/2025Marshall Wace LLP203,286$213K0.0%N/A0.271% 2/13/2025Affinity Asset Advisors LLC1,015,340$1.07M0.1%-23.1%1.354% 2/13/2025Walleye Capital LLC166,306$175K0.0%+51.7%0.222% SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.See how to get positioned in SpaceX before the announcement goes public2/13/2025Renaissance Technologies LLC338,435$355K0.0%+412.8%0.451% 2/13/2025ADAR1 Capital Management LLC351,094$369K0.1%-6.1%0.468% 2/12/2025Landscape Capital Management L.L.C.90,000$94K0.0%N/A0.120% 2/12/2025Geode Capital Management LLC628,729$661K0.0%+9.2%0.838% 2/12/2025Franklin Resources Inc.4,003,380$4.20M0.0%+115.9%5.338% 1/17/2025Clear Harbor Asset Management LLC57,804$61K0.0%+60.6%0.077% 11/27/2024Franklin Resources Inc.1,853,988$3.69M0.0%N/A2.472% 11/16/2024Geode Capital Management LLC575,899$1.13M0.0%-6.8%0.768% 11/15/2024Y Intercept Hong Kong Ltd45,635$89K0.0%N/A0.061% 11/15/2024State Street Corp111,907$219K0.0%+21.5%0.149% 11/14/2024Ally Bridge Group NY LLC1,757,524$3.45M1.8%-6.8%2.343% 11/13/2024Great Point Partners LLC6,934,982$13.59M4.0%-6.5%9.247% 8/20/2024Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% 8/16/2024Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% 8/15/2024Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% 2/16/2023AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501% CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 35 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were MPM Bioimpact LLC ($15.70M), Octagon Capital Advisors LP ($13.76M), Great Point Partners LLC ($13.59M), Blue Owl Capital Holdings LP ($10.93M), Avidity Partners Management LP ($8.09M), Driehaus Capital Management LLC ($4.53M), and Franklin Resources Inc. ($4.20M).Learn more on Context Therapeutics' institutional investors. What percentage of Context Therapeutics' stock is owned by institutional investors? 14.03% of Context Therapeutics' stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics' stock? Of the 30 institutional investors that purchased Context Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: MPM Bioimpact LLC ($14.71M), Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($6.13M), Octagon Capital Advisors LP ($5.25M), Franklin Resources Inc. ($4.00M), Marshall Wace LLP ($2.76M), and Millennium Management LLC ($2.64M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 11,287,698 shares in the last 24 months. This purchase volume represents approximately $22.74M in transactions. Which of Context Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Context Therapeutics stock in the last 24 months: MPM Bioimpact LLC ($4.03M), Avidity Partners Management LP ($3.48M), Nantahala Capital Management LLC ($1.90M), Renaissance Technologies LLC ($325.33K), Affinity Asset Advisors LLC ($142.56K), Qube Research & Technologies Ltd ($92.20K), and Walleye Capital LLC ($36.17K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 9,997,404 shares in the last 24 months. This volume of shares sold represents approximately $14.72M in transactions. Related Companies XNCR Major Shareholders EVMN Major Shareholders AMPH Major Shareholders LBRX Major Shareholders VOR Major Shareholders SPRY Major Shareholders BIOA Major Shareholders ANRO Major Shareholders DRUG Major Shareholders IVA Major Shareholders This page (NASDAQ:CNTX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
